.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Chinese Patent Office
UBS
Citi
Mallinckrodt
Novartis
McKinsey
Covington
Chubb
Colorcon

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,417,148

« Back to Dashboard

Which drugs does patent 7,417,148 protect, and when does it expire?


Patent 7,417,148 protects BOSULIF and is included in one NDA. There has been one Paragraph IV challenge on Bosulif.

This patent has nineteen patent family members in seventeen countries.

Summary for Patent: 7,417,148

Title:4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Abstract: Compounds of the formula: ##STR00001## wherein: n is an integer from 1-3; X is N, CH, provided that when X is N, n is 2 or 3; R is alkyl of 1 to 3 carbon atoms; R.sup.1 is 2,4-diCl, 5-OMe; 2,4-diCl; 3,4,5-tri-OMe; 2-Cl, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCl, 5-OEt; R.sup.2 is alkyl of 1 to 2 carbon atoms, and pharmaceutically acceptable salts thereof.
Inventor(s): Boschelli; Frank (New City, NY), Arndt; Kim T. (Towaco, NJ), Golas; Jennifer M. (Hewitt, NJ)
Assignee: Wyeth (Madison, NJ)
Application Number:10/980,097
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes7,417,148► Subscribe A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-002Sep 4, 2012RXYesNo7,417,148► Subscribe A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,417,148

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,919,6254-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,417,148

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Singapore146681► Subscribe
Russian Federation2006113691► Subscribe
Norway20062255► Subscribe
MexicoPA06004744► Subscribe
South Korea20060118461► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Harvard Business School
Cerilliant
Novartis
Fish and Richardson
QuintilesIMS
Citi
McKinsey
Federal Trade Commission
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot